|
Indivior PLC on Monday announced it is resolving claims brought in antitrust multi-district litigation regarding its drug Suboxone by paying claimants millions of dollars. The Virginia-headquartered pharmaceutical company, which specialises in treating addiction and mental illness said it has agreed to pay $30 million to end payor claimants. This is in line with its current provision of $188 million for the multi-district litigation. Suboxone is a medicine to treat dependence on opioid drugs such as heroin or morphine. The claims were brought by the attorney generals of 41 states and the District of Columbia. They claim the company violated US federal and state antitrust and consumer protection laws in attempting to delay the generic entry of alternatives to Suboxone. The payment is subject to initial approval by the United States District Court for the Eastern District of Pennsylvania and participation by an appropriate number of end payors and final approval of the court. ‘We remain focused on helping those suffering from substance use disorders and mental illness,’ said Chief Executive Officer Mark Crossley. ‘Resolving these legacy legal matters at the right value helps us further our mission for patients and creates greater certainty for our stakeholders.’ Indivior shares rose 1.8% to 1,791.00 pence each on Monday morning in London. Copyright 2023 Alliance News Ltd. All Rights Reserved.
|
